Full Text PA-95-009 PREDICTION AND DETERMINATION OF HEARING AID BENEFIT NIH GUIDE, Volume 23, Number 42, December 2, 1994 PA NUMBER: PA-95-009 P.T. 34 Keywords: Prosthetic Device, Hearing Treatment, Medical+ National Institute on Deafness and Other Communication Disorders PURPOSE The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the support of basic and applied research studies on issues related to predicting and measuring the benefit received from hearing aids. No widely accepted measures of hearing aid benefit are currently available, nor is there a universally accepted definition of hearing aid benefit. In addition, clinical measures currently used for fitting hearing aids provide little of value in predicting user benefit, especially over the long term. Clinicians and researchers agree that many more individuals than currently use hearing aids could benefit from their use. Rational approaches to designing and providing hearing aids to millions of hearing-impaired individuals require clinically valid measures for predicting and determining the benefit received from hearing aids. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Prediction and Determination of Hearing Aid Benefit, is related to the priority area of diabetes and chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state or local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Applications from minority individuals, women, and individuals with disabilities are encouraged. MECHANISM OF SUPPORT The support mechanisms for grants in this area will be the individual investigator-initiated research project grant (R01) and the FIRST (R29) award. RESEARCH OBJECTIVES A variety of cosmetically acceptable hearing aids, with a wide range of processing capabilities, is available to millions of hearing- impaired people. Anatomical, physiological, and psychophysical studies have provided a better understanding of the abilities and limitations of the normal and impaired auditory system. Clinical tools such as real ear acoustic measures and hearing aid prescriptive procedures have made the fitting of hearing aids a more precise process. Although these advances have facilitated the provision of high-quality hearing aids, most clinicians are uncertain to what extent a given hearing aid will benefit a given individual, especially over the longterm. Lack of knowledge about what constitutes or defines benefit for a given person contributes to this problem. Hearing aid benefit has been defined in many ways, including: any reported improvement in a person's quality of life related to the use of a hearing aid; a measurable improvement in the ability to understand speech; a perceived improvement in the quality of sound; the number of hours of actual hearing aid use; and a decision by a hearing aid candidate to keep or return a hearing aid. The two main approaches to assessing hearing aid benefit have been self-report inventories and speech intelligibility measures. Although each of these approaches has provided useful information, neither has led to widely accepted valid evaluation endpoints for the prediction or determination of hearing aid benefit. Measures of definitive evaluation endpoints, or definitive outcome measures, are those that define the actual long-term benefit received from a hearing aid. Surrogate evaluation endpoints are intended to be related to or predictive of the definitive evaluation endpoint. Measures of both definitive and surrogate evaluation endpoints are needed. Surrogate measures allow clinical practice and research to continue and advance as better tests are developed and as the relationship between outcome on tests and benefit is further elucidated. For example, surrogate measures are important in clinical practice for determining candidacy for a hearing aid and for differentiating between hearing aids with respect to expected benefit. A continuum of evaluation endpoints probably exists. A set of measures more time-intensive than a typical clinical measure, but less so than a definitive research measure, might be used in clinical research studies of hearing aid benefit. Studies of evaluation endpoints along the entire continuum are needed. Previous studies indicate that many factors may contribute to hearing aid benefit. Such factors include: individual characteristics such as performance on psychoacoustic tests, personality traits, and cognitive factors; aspects of the acoustic environment such as noise and reverberation; the degree and type of hearing loss; the type of communication tasks required of the individual hearing aid wearer; and factors related to the performance of the hearing aid itself, such as audibility, distortion, and signal processing. Other parameters, such as learning and adaptation effects associated with hearing aid use over time, may also affect hearing aid benefit. Not only do the factors contributing to hearing aid benefit need to be identified and characterized systematically, but the interaction among these factors also needs to be explored. This initiative encourages both basic and applied research designed to contribute to the understanding of and to the development of measures for the prediction and determination of hearing aid benefit. An important factor in such studies is the ability to generalize findings to hearing-impaired individuals with respect to degree and type of hearing loss and to age. Since some or all of the variables described above may vary for different subgroups of the hearing- impaired population, this should be taken into account in study designs, as appropriate. A variety of approaches to the research problems is encouraged, and topics may include, but are not limited to those listed below: o development of a clear, rational, and evidence-based characterization of hearing aid benefit, based on valid definitive evaluation endpoints (e.g., communication benefit, comfort, ease of use, perceived impairment) capable of predicting and measuring hearing aid benefit o determination of surrogate evaluation endpoints that relate to and are predictive of definitive evaluation endpoints in both clinical and research settings o development of valid and reliable tests to measure surrogate and definitive evaluation endpoints in both clinical and research settings o determination of both the auditory and nonauditory factors that contribute to hearing aid benefit, including those related to the individual hearing aid wearer, to the acoustic environment, to the hearing aid, and to learning or adaptation effects o characterization of the relationships between the auditory and nonauditory factors that contribute to hearing aid benefit o development of valid and reliable tests to measure the factors that contribute to hearing aid benefit, with a special emphasis on measures that are predictive of long-term benefit o development of measures of hearing aid benefit appropriate to children and other special populations (i.e., measures that are maximally sensitive to sensory processes, but minimally affected by cultural, linguistic and cognitive status) INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available from most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 710-0267. The title and number of the announcement must be typed in Section 2a on the face page of the application. Applications for the FIRST Award (R29) must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award (R29) applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Applications will be assigned on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications will receive a second-level review by the appropriate national advisory council. As part of the initial merit review, a process (triage) will be used by the initial review group in which applications will be determined to be competitive or non-competitive based on their scientific merit relative to other applications received in response to the PA. Applications judged to be competitive will be discussed and be assigned a priority score. Applications determined to be non- competitive will be withdrawn from further consideration and the Principal Investigator and the official signing for the applicant organization will be notified. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o Adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. AWARD CRITERIA Applications will compete for available funds with all other applications assigned to that Institute or Center. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program priorities among research areas of the program announcement INQUIRIES Written and telephone inquiries concerning this PA are encouraged; the opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding scientific content to: Lynn E. Huerta, Ph.D. Division of Human Communication National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400-C 6120 Executive Boulevard MSC 7180 Bethesda, MD 20892-7180 Telephone: (301) 402-3461 FAX: (301) 402-6251 E-Mail: Lynn_Huerta%NIDCD-EPS%NIH@FEDTCP.NINDS.NIH.GOV Direct inquiries regarding fiscal matters to: Sharon Hunt Grants Management Office National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400-B 6120 Executive Boulevard MSC 7180 Bethesda, MD 20892-7180 Telephone: (301) 402-0909 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.173. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service strongly encourages all grant recipients to provide a smokefree workplace and promote the nonuse of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||